Drug Trial Radar · NCT00744497
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Oct 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,930
Actual
Start
Oct 2008
Primary completion
Aug 2012
Study completion Jul 2015
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Sep 1, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether survival can be prolonged in patients with castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.
Conditions
- Prostatic Neoplasms
Interventions
PlaceboDrug
DasatinibDrug
DocetaxelDrug
PrednisoneDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival: Time From Randomization to Date of DeathTime frame: From randomization to death or date of last contact (maximum reached: 45 months)
Locations
186 sites in 25 countries. Site status is shown where the registry gives one.
University Of South Alabama / Mitchell Cancer Institute
Mobile, Alabama
Southern Cancer Center
Mobile, Alabama
Alaska Clinical Research Center, Llc
Anchorage, Alaska
Highlands Oncology Group
Fayetteville, Arkansas
Compassionate Cancer Care Medical Group, Inc.
Corona, California
Desert Hematology Oncology Medical Group
Rancho Mirage, California
Compassionate Cancer Care Medical Group Inc
Riverside, California
Sharp Clinical Oncology Research
San Diego, California
Va San Diego Healthcare System
San Diego, California
Edward Alexson, Md, Inc.
Santa Ana, California
Connecticut Oncology Group
Middletown, Connecticut
Va Connecticut Healthcare System
West Haven, Connecticut
Gwinnett Hospital System Inc.
Lawrenceville, Georgia
University Of Chicago
Chicago, Illinois
Midwestern Regional Medical Center
Zion, Illinois
Fort Wayne Medical Oncology And Hematology Inc
Fort Wayne, Indiana
Cancer Center Of Kansas
Wichita, Kansas
Maine Center For Cancer Medicine
Scarborough, Maine
Tufts Medical Center
Boston, Massachusetts
Jackson Oncology Associates, Pllc
Jackson, Mississippi
North Mississippi Hematology And Oncology Associates, Ltd
Tupelo, Mississippi
New York Oncology Hematology, Pc
Albany, New York
New York Oncology Hematology, Pc
Albany, New York
Samuel S. Stratton Vamc
Albany, New York
Roswell Park Cancer Institute
Buffalo, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Piedmont Hematology Oncology Associates, Pllc
Winston-Salem, North Carolina
Summa Health System
Akron, Ohio
Mid Ohio Oncology/Hematology, Inc,Dba
Columbus, Ohio
Providence Portland Med Ctr
Portland, Oregon
Regional Hemetology Oncology, Pc
Langhorne, Pennsylvania
Upmc Cancer Pavilion
Pittsburgh, Pennsylvania
Va Pittsburgh Healthcare System
Pittsburgh, Pennsylvania
Associates In Hematology & Oncology, P.C.
Upland, Pennsylvania
The Miriam Hospital
Providence, Rhode Island
Cancer Centers Of The Carolinas
Greenville, South Carolina
Boston Baskin Cancer Foundation
Memphis, Tennessee
Cancer Specialists Of South Texas, Pa
Corpus Christi, Texas
The University Of Texas Md Anderson Cancer Center
Houston, Texas
Showing 40 of 186 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.